SciSparc Ltd. business relationships
Companies named in SciSparc Ltd.’s 20-F filed 2026-04-29, and public companies whose annual reports name SciSparc Ltd.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 72 / 100 Top 2% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in SciSparc Ltd.’s annual report 10
“and other third-party delivery agents and online retailers, mainly Amazon.” SEC filing
“and utilize data, including search engine results, provided by unaffiliated third parties, primarily, Google and Amazon.” SEC filing
“the customer depends on third parties outside of our control, including suppliers and logistics providers such as FedEx, UPS, postal services” SEC filing
“the customer depends on third parties outside of our control, including suppliers and logistics providers such as FedEx, UPS, postal services” SEC filing
“Our customers may engage with us online through our social media platforms, including Facebook and Instagram,” SEC filing
“and utilize data, including search engine results, provided by unaffiliated third parties, primarily, Google and Amazon.” SEC filing
“For example, our collaboration with Clearmind Medicine Inc.,” SEC filing
“On August 13, 2024, the Company entered into the license agreement (the "License Agreement") of the out-licensing of its SCI-160 program (the "Assets"), with Polyrizon Ltd. (the "Licensee" or "Polyrizon").” SEC filing
“In addition, in August 2024, we entered into an exclusive patent license agreement with Polyrizon Ltd.,” SEC filing
“into a collaboration agreement with Polyrizon, a biotech company focused on the development of innovative medical device hydrogels delivered” SEC filing
Companies whose annual reports name SciSparc Ltd. 4
“ongoing collaboration with SciSparc, we entered into a research agreement with the Hebrew University of Jerusalem to evaluate our and” SEC filing
“to the terms of the SciSparc License Agreement, SciSparc is entitled to up to $3.32 million based on the achievement of certain milestones,” SEC filing
“In accordance with the collaboration agreement, SciSparc will pay development fees to the Company upon successful completion of clinical trials, of $ 80 by successful completion of preclinical safety tests, $ 120 by successful completion of Phase 1 clinical trial, $ 150 by upon successful completion...” SEC filing
“services are provided in collaboration with SciSparc.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.